Synthesis 2016; 48(09): 1318-1321
DOI: 10.1055/s-0035-1561917
psp
© Georg Thieme Verlag Stuttgart · New York

Kilogram Synthesis of Crebinostat

Yongjun Mao*
College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, 333 Longteng Road, Shanghai 201620, P. R. of China   Email: yongjun.mao@hotmail.com
,
Chunping Zhu
College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, 333 Longteng Road, Shanghai 201620, P. R. of China   Email: yongjun.mao@hotmail.com
,
Guoqing Zhu
College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, 333 Longteng Road, Shanghai 201620, P. R. of China   Email: yongjun.mao@hotmail.com
,
Han Wang
College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, 333 Longteng Road, Shanghai 201620, P. R. of China   Email: yongjun.mao@hotmail.com
,
Xinfeng Ren
College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, 333 Longteng Road, Shanghai 201620, P. R. of China   Email: yongjun.mao@hotmail.com
› Author Affiliations
Further Information

Publication History

Received: 11 February 2016

Accepted: 15 February 2016

Publication Date:
11 March 2016 (online)


Abstract

A kilogram-scale synthetic route to crebinostat, a small molecule inhibitor of histone deacetylases (HDACs), is developed successfully. Starting from pimelic acid, dimethyl pimelate is obtained in high yield via methyl esterification. The latter is ammoniated by hydrazine and hydroxylamine successively to give the key intermediate 7-hydrazinyl-N-hydroxy-7-oxoheptanamide, which is coupled with 4-biphenylcarboxaldehyde in ethanol to give crebinostat in 37% yield over four steps. The final product with 99.5% total purity (HPLC) contains E/Z-isomers in a ratio of around 1.3:1, which is confirmed by 1H NMR spectroscopy. Purification methods of the intermediates and the final product involved in the route are given, which make this process environmentally friendly, cost-effective, and feasible for scale-up operation.

 
  • References

  • 1 Fass DM, Reis SA, Ghosh B, Hennig KM, Joseph NF, Zhao WN, Nieland TJ, Guan JS, Kuhnle CE, Tang W, Barker DD, Mazitschek R, Schreiber SL, Tsai LH, Haggarty SJ. Neuropharmacology 2013; 64: 81
  • 2 Bradner JE, Mazitschek R, Tang W, Schreiber SL. Patent WO 2008091349, 2008
  • 3 Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. Leuk. Lymphoma 2016; in press; DOI: 10.3109/10428194.2015.1135431
  • 4 Afifi S, Michael A, Azimi M, Rodriguez M, Lendvai N, Landgren O. Pharmacotherapy 2015; 35: 1173
  • 5 Stolfa DA, Marek M, Lancelot J, Hauser AT, Walter A, Leproult E, Melesina J, Rumpf T, Wurtz JM, Cavarelli J, Sippl W, Pierce RJ, Romier C, Jung M. J. Mol. Biol. 2014; 426: 3442
  • 6 Tang W, Luo T, Greenberg EF, Bradner JE, Schreiber SL. Bioorg. Med. Chem. Lett. 2011; 21: 2601
  • 7 Chen Y, Lan Y, Wang S, Zhang H, Xu X, Liu X, Yu M, Liu BF, Zhang G. Eur. J. Med. Chem. 2014; 74: 427